Anti-CD25 monoclonal antibody (basiliximab) for prevention of graft-versus-host disease after haploidentical bone marrow transplantation for hematological malignancies.

摘要: Haploidentical donors are available for most patients who need allografts but do not have matched donors. However, GVHD, rejection, delayed immune reconstitution, and infections been significant barriers. We designed a haploidentical BMT protocol focusing on prevention of GVHD rejection. A total 53 leukemic underwent G-CSF-primed without ex vivo T-cell depletion. prophylaxis consisted antithymocyte globulin, cyclosporine, methotrexate, mycophenolate mofetil. In all, 38 (the CD25 group) received additional anti-CD25 monoclonal antibody basiliximab. The results were compared to 15 did receive All achieved trilineage engraftment with full-donor chimerism. incidence acute II-IV was 11% in the group vs 33% control (P=0.046). overall extensive chronic 15%. T, B, NK cells recovered within 12 months post transplant. disease-free survival at 2 years 53% median follow-up 31 months. conclusion, G-CSF primed along sequential immunosuppressive agents as described here deserves further study.